30-Apr-04
09:43 GNTA Genta lower on FDA staff comments (12.60 -1.83)
Stock trades down 12.6% following Reuters report that the FDA staff review says Genasense trial results could be "Falsely positive." (Briefing.com note: Our sources indicate the somewhat negative comments were expected...